Dr. Pradhan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
900 Commonwealth Ave
Boston, MA 02215Phone+1 617-278-8777
Education & Training
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2002 - 2005
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1996 - 1999
Georgetown University School of MedicineClass of 1996
Certifications & Licensure
MA State Medical License 1999 - 2024
Clinical Trials
- The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes Start of enrollment: 2006 Aug 01
- Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes Start of enrollment: 2010 Sep 01
- Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) Start of enrollment: 2017 Mar 23
Publications & Presentations
PubMed
- 1 citationsBiomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial.Frank Qian, Yanjun Guo, Chunying Li, Yanyan Liu, Heike Luttmann-Gibson
Cardiovascular Diabetology. 2024-11-02 - Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT.Lucas L Marinho, Brendan M Everett, Aaron W Aday, Frank L J Visseren, Jean G MacFadyen
Journal of the American College of Cardiology. 2024-07-23 - 18 citationsC-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations.Pascal M Burger, Aruna D Pradhan, Jannick A N Dorresteijn, Stefan Koudstaal, Martin Teraa
The American Journal of Cardiology. 2023-06-15
Journal Articles
- Trial Designs Rationale and Design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) Study☆Marshall Elam, Aruna D Pradhan, William R Hiatt, ScienceDirect
Press Mentions
Pemafibrate Takes a Small Step Forward in Diabetic Foot Ulcers After CVD FlopJuly 15th, 2024- Pemafibrate Reduces Triglycerides, but Not CV Events, in Patients with T2D, HypertriglyceridemiaDecember 23rd, 2022
- Scientists Discover Surprising Effect Cholesterol-Lowering Drug Has on Heart Disease RiskNovember 14th, 2022
- Join now to see all
Grant Support
- Mechanisms Of Statin-Induced DM In Jupiter (Rosuvasatin For CVD Prevention)National Heart, Lung, And Blood Institute2010–2011
- Novel And Traditional Risk Factors For Symptomatic PAD In WomenNational Heart, Lung, And Blood Institute2007–2010
- Novel/Traditional Risk Factors--Symptomatic PAD In WomenNational Heart, Lung, And Blood Institute2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
